Methods of inhibiting cancer stem cells with hmga1 inhibitors
US-2015315589-A1 · Nov 5, 2015 · US
Means and methods for reducing tumorigenicity of cancer stem cells
US11174484B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11174484-B2 |
| Application number | US-201615774795-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 10, 2016 |
| Priority date | Nov 10, 2015 |
| Publication date | Nov 16, 2021 |
| Grant date | Nov 16, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are RNA inhibitory molecules, particularly siRNA molecules silencing the expression of Voltage-Dependent Ion Chanel-1 (VDAC1) for the induction of cancer stem cell differentiation and reduction of TAMs abundance and tumor angiogenesis, thereby preventing tumor invention and recurrence.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for inducing the transition of a cancer stem cell and/or quasi differentiated cancer cell to a differentiated cell, the method comprising administrating to, or expressing in the cancer stem cell or quasi differentiated cancer cell an effective amount of a voltage dependent anion channel 1 (VDAC1)-silencing oligonucleotide, comprising the nucleic acid sequence set forth in SEQ ID NO:3 and a complementary sequence thereto. 2. The method of claim 1 , wherein the cancer stem cell and/or quasi differentiated cancer cell form part of a tumor of a subject. 3. The method of claim 1 , wherein the cancer stem cell and/or quasi differentiated cancer cell is within a cell or tissue culture.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
involving nucleic acids · CPC title
for cancer (immunoassay for cancer G01N33/575) · CPC title
Prognosis of disease development · CPC title
- C12N15/1138Primary
against receptors or cell surface proteins · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11174484B2 cover?
- Provided are RNA inhibitory molecules, particularly siRNA molecules silencing the expression of Voltage-Dependent Ion Chanel-1 (VDAC1) for the induction of cancer stem cell differentiation and reduction of TAMs abundance and tumor angiogenesis, thereby preventing tumor invention and recurrence.
- Who is the assignee on this patent?
- B G Negev Technologies And Applications Ltd At Ben Gurion Univ, Nat Inst Biotechnology Negev Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1138. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).